March 3, 2026Open Access

Real-world efficacy and prognostic factors of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: a multicenter retrospective study from the Dongting Lake region of China

Puntos clave

Real-world efficacy of CDK4/6 inhibitors shows favorable outcomes in HR+/HER2− metastatic breast cancer patients.
In this study, patients experienced significant benefits when using CDK4/6 inhibitors as a first-line treatment.
Retrospective analysis across multiple centers in central China highlights the role of clinical factors in treatment decisions.
Identifying prognostic factors could enhance treatment selection and risk stratification for better patient outcomes.

Resumen

CDK4/6i demonstrates favorable real-world efficacy in HR+/HER2- MBC patients in central China, particularly in the first-line setting. Several clinical factors may aid in treatment selection and risk stratification.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Liu et al. (Thu,) studied this question.

synapsesocial.com/papers/69a75d3cc6e9836116a26ee0 — DOI: https://doi.org/10.21037/tbcr-25-37

Authors

Binliang Liu

Central South University

Tao Wu

Central South University

Kaili Lu

Yantai Laiyang Central Hospital

Journals

Translational Breast Cancer Research

Actions

Institutions

Central South University

Shanghai University of Traditional Chinese Medicine

Hunan Cancer Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Real-world efficacy and prognostic factors of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: a multicenter retrospective study from the Dongting Lake region of China

Puntos clave

Resumen

Citation Network

Connected Papers

Discussion

Cite this study

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion